Loading...
Loading...
XNCR| Name | Value |
|---|---|
| Revenues | 45.5M |
| Cost of Revenue | 2.9M |
| Gross Profit | 42.6M |
| Operating Expense | 71.5M |
| Operating I/L | -26.0M |
| Other Income/Expense | 4.0M |
| Interest Income | 3.8M |
| Pretax | -22.0M |
| Income Tax Expense | -2.9M |
| Net Income/Loss | -22.0M |
Xencor, Inc. is a clinical stage biopharmaceutical company specializing in engineered monoclonal antibody and cytokine therapeutics for cancer and autoimmune diseases. Its product portfolio includes Sotrovimab for SARS-CoV-2, Ultomiris for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, and Monjuvi for relapsed or refractory diffuse large B-cell lymphoma. The company is also developing a range of antibody and cytokine therapeutics in various stages of clinical trials for conditions such as non-Hodgkin lymphoma, prostate cancer, neuroendocrine tumors, autoimmune diseases, hepatitis B virus infection, influenza A, and COVID-19. Additionally, it is working on treatments for allergic responses, autoimmune diseases, and neurological conditions.
